Clearstead Advisors, LLC Trevi Therapeutics, Inc. Transaction History
Clearstead Advisors, LLC
- $7.4 Billion
- Q3 2025
A detailed history of Clearstead Advisors, LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 39 shares of TRVI stock, worth $441. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39Holding current value
$441% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TRVI
# of Institutions
180Shares Held
113MCall Options Held
1.07MPut Options Held
425K-
Nea Management Company, LLC Timonium, MD13.2MShares$150 Million6.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$116 Million3.88% of portfolio
-
Rubric Capital Management LP New York, NY8.53MShares$96.7 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.83MShares$66 Million0.0% of portfolio
-
Marshall Wace, LLP London, X04.84MShares$54.9 Million0.05% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $661M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...